Gene Silencing Porphyria Treatment, Givlaari, Finally Wins Over England’s NICE Amid Stellar Long-Term Data
XTalks
OCTOBER 26, 2021
The treatment came with an initial price tag of $39,000 per vial, which amounts to a total of $575,00 each year. The data was presented at the virtual United European Gastroenterology (UEG) Week 2021. Givlaari was approved by the European Medicines Agency (EMA) in March 2020 and by the US Food and Drug Administration ( FDA ) in 2019.
98 
Let's personalize your content